We validated the synergy of BR using three additional KRAS mutant CRC cells (DLD1, SW480 and LS180) and viability assay with combination index calculated (CI < 0.5) (Fig. 1a-b). The gene discussed is KRAS; the disease is colorectal carcinoma.